Mammary Cell News 12.07 February 27, 2020 | |
| |
TOP STORYCrosstalk with Lung Epithelial Cells Regulates Sfrp2-Mediated Latency in Breast Cancer Dissemination Researchers revealed how the behavior of indolent breast cancer cells in the lung is determined by their interactions with alveolar epithelial cells, in particular alveolar type 1 cells. This promoted the formation of fibronectin fibrils by indolent cells that drove integrin-dependent pro-survival signals. [Nat Cell Biol] Abstract | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)Autophagic Degradation of NBR1 Restricts Metastatic Outgrowth during Mammary Tumor Progression Scientists utilized mammary cancer models to temporally delete essential autophagy regulators during carcinoma progression. Though genetic ablation of autophagy strongly attenuated primary mammary tumor growth, impaired autophagy promoted spontaneous metastasis and enabled the outgrowth of disseminated tumor cells into overt macro-metastases. [Dev Cell] Full Article | Graphical Abstract Circular RNA (CircRNA) microarray sequencing revealed that circRNF20 was one of the upregulated transcripts in breast cancer (BC) samples. Increased circRNF20 level predicted the poor clinical outcome in BC specimens. Functionally, circRNF20 promoted the proliferation and Warburg effect of BC cells. [Cell Death Dis] Full Article Scientists identified drug response-related lncRNAs (DRlnc) by combining expression data of lncRNA, microRNA, messenger RNA, methylation levels, and somatic mutations, and the survival data of cancer patients treated with drugs. They constructed an integrated and computational multi-omics approach to identify DRlncs for diverse chemotherapeutic drugs in BRCA. [Mol Ther Nucleic Acids] Abstract | Full Article The development of dual-sensitive nanogels was described that were designed to rapidly dislodge the chemotherapy drug, doxorubicin, inside cancer cells through dual-sensitive action-pH and redox sensitivities-enabling efficient cancer-cell killing while eliminating systemic side effects. [Adv Healthc Mater] Abstract The authors demonstrated that miR-155 was upregulated in CD24–CD44+ breast cancer (BC) stem cells (BCSCs). In addition, the overexpression of miR-155 increased the number of CD24–CD44+ cancer stem cells, decitabine resistance and tumor clone formation in MDA-231 BC cells, and knockdown of miR-155 inhibited decitabine resistance and stemness in BCSCs in vitro. [Mol Carcinog] Abstract Researchers used in silico studies with biological validation of the molecular targets for the anti-breast cancer mechanism of atranorin. The molecular docking studies with the breast cancer oncoproteins such as Bcl-2, Bax, Akt, Bcl-w and Bcl-xL revealed the highest interaction was observed with the Akt followed by Bax, Bcl-xL and Bcl-2, and least with the Bcl-w proteins. [J Biomol Struct Dyn] Abstract The authors used different concentrations of recombinant Taenia solium calreticulin (rTsCRT) to treat cancer cell lines and analyzed viability and colony formation capacity. They also tested the combination of the IC20 or IC50 doses of rTsCRT and of the chemotherapeutic drug 5-fluorouracil on MCF7 and SKOV3 cell lines. As a control, the non-tumorigenic cell line MCF10-A was employed. [Arch Med Res] Full Article | Graphical Abstract Investigators determined the molecular features of breast cancer–associated myeloid-derived suppressor cells using the widely studied mouse model based on the mouse mammary tumor virus promoter-driven expression of the polyomavirus middle T oncoprotein. [Sci Immunol] Abstract Subscribe to one of our other 19 science newsletters such as Prostate Cell News & ESC & iPSC News. | |
| |
REVIEWSThe authors present the case for including information on DNA methylation marks to improve the accuracy of these risk prediction models, and consider how this approach contrasts genetic information, as identifying DNA methylation marks associated with breast cancer risk differs inherently according to the source of DNA, approaches to the measurement of DNA methylation, and the timing of measurement. [Br J Cancer] Full Article Visit our reviews page to see a complete list of reviews in the mammary cell research field. | |
| |
INDUSTRY NEWSCytoDyn Inc. reported that it has received Institutional Review Board (IRB) approval to begin its Phase II clinical trial for the treatment of approximately 22 different solid tumor cancers, including melanoma, brain-glioblastoma, throat, lung, stomach, colon carcinoma, breast, testicular, ovarian, uterine, pancreas, bladder, among other indications. [CytoDyn Inc.] Press Release UCLA Raises $5.49 Billion in One of Most Ambitious Campaigns Ever by a Public University The Centennial Campaign for University of California, Los Angeles (UCLA) has raised $5.49 billion. As UCLA enters its second century, the funds are already supporting a broad array of priorities, including student scholarships and fellowships, faculty research, and programs that enrich communities in Los Angeles and beyond. [University of California, Los Angeles] Press Release MTF Biologics Awards $1.8 Million in 2019 Extramural Research Grants MTF Biologics has awarded over $1.8 million in funding to twelve researchers across the nation through its 2019 Extramural Research Grants Program. [MTF Biologics (Business Wire, Inc.)] Press Release | |
| |
POLICY NEWSFederal Judge Rules Clinical Trial Sponsors Must Publish a Decade’s Worth of Missing Data For years, government research agencies have misinterpreted a law that requires them to collect and post clinical trial data, a federal judge ruled this week, leaving behind a 10-year gap in data that now must be made publicly available. [STAT News] Editorial It was the fall of 2015 when researchers from Google and the University of California, San Francisco, first sat down together to hash out a research collaboration in an area that has since exploded with activity: using artificial intelligence to make predictions in the hospital. [STAT News] Editorial
| |
EVENTSNEW Tissue Stem Cell Regulation by Autonomous and Non-Autonomous Mechanisms Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Research Assistant – 3D Models of Breast Cancer (University of Cambridge) Postdoctoral Associate – Oncology (University of Miami Health System) Postdoctoral Research Position – Breast Cancer Research (The University of Texas) Postdoctoral Position – Breast Cancer Metastasis (University of Kentucky) Research Fellow – Breast Cancer (Dana-Farber Cancer Institute) Postdoctoral Fellow – Breast Tumorigenesis (University of Cincinnati) Postdoctoral Position – DNA Nanotechonology in Cancer (University of Duisburg-Essen) Postdoctoral Fellow – Clonal Evolution of Cancer (Moffitt Cancer Center & Research Institute) Investigator Position – Cancer Cell Biology (Winthrop P. Rockefeller Cancer Institute) Postdoctoral Research Fellow – Breast Cancer Research (University of South Carolina) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Mammary Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|